Select Publications
Conference Presentations
2023, 'Innovations beyond BC: Lisdexamfetamine for the treatment of methamphetamine use disorder and withdrawal', presented at The 5th Annual BC Substance Use Conference, Vancouver, Canada, 20 April 2023 - 23 April 2023
,2022, 'An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial', presented at Lisbon Addictions, Lisbon, Portugal, 23 November 2022 - 25 November 2022
,2022, 'Safety and tolerability of lisdexamfetamine for methamphetamine dependence and withdrawal, early experience from Australia: The LiMA Trial and OLAM pilot', presented at Annual Meeting Conference of the Norwegian Association for Addiction Medicine, Bergen, Norway, 02 November 2022
,2022, 'Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial', presented at The 2022 APSAD Scientific Alcohol and Drugs Conference, Darwin, Australia, 09 October 2022 - 12 October 2022, https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13537
,2022, 'OUTCOMES AND MEASURES USED IN RANDOMISED CONTROLLED TRIALS EXAMINING PHARMACOTHERAPIES FOR THE TREATMENT OF METHAMPHETAMINE WITHDRAWAL: RESULTS OF A SYSTEMATIC REVIEW', presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 July 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2022, 'Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials', presented at RANZCP 2022 Congress, Sydney, 15 May 2022 - 19 May 2022, http://dx.doi.org/10.1177/00048674221088686
,2021, 'The future of pharmacotherapy clinical trials in Australia: the OLAM trial; the MOXY trial; the PSIMA trial; the TINA trial', presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,